Published in J Clin Invest on June 15, 1996
Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin. J Clin Invest (1999) 3.30
Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A (1999) 2.66
Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates. J Bone Miner Res (2008) 2.42
Changes in non-enzymatic glycation and its association with altered mechanical properties following 1-year treatment with risedronate or alendronate. Osteoporos Int (2008) 1.85
Oncologic doses of zoledronic acid induce osteonecrosis of the jaw-like lesions in rice rats (Oryzomys palustris) with periodontitis. J Bone Miner Res (2012) 1.73
Connexin 43 is required for the anti-apoptotic effect of bisphosphonates on osteocytes and osteoblasts in vivo. J Bone Miner Res (2008) 1.68
Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci U S A (1998) 1.63
Breast cancer chemoprevention: old and new approaches. J Biomed Biotechnol (2012) 1.57
Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis. Oncologist (2013) 1.54
Tumour macrophages as potential targets of bisphosphonates. J Transl Med (2011) 1.53
Parathyroid hormone mediates bone growth through the regulation of osteoblast proliferation and differentiation. Bone (2007) 1.40
The epidemiology of distal radius fractures. Hand Clin (2012) 1.40
Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol (2003) 1.38
Myeloid derived suppressor cells - a new therapeutic target in the treatment of cancer. J Immunother Cancer (2013) 1.35
Osteoblastic responses to TGF-beta during bone remodeling. Mol Biol Cell (1998) 1.28
Cancer treatment dosing regimens of zoledronic acid result in near-complete suppression of mandible intracortical bone remodeling in beagle dogs. J Bone Miner Res (2010) 1.25
Prevention and treatment of systemic glucocorticoid side effects. Int J Dermatol (2010) 1.07
Myeloid derived suppressor cells-An overview of combat strategies to increase immunotherapy efficacy. Oncoimmunology (2015) 1.03
Morphological assessment of basic multicellular unit resorption parameters in dogs shows additional mechanisms of bisphosphonate effects on bone. Calcif Tissue Int (2009) 1.01
Osteoporosis and gastrointestinal disease. Gastroenterol Hepatol (N Y) (2010) 0.99
Bisphosphonates and osteonecrosis of the jaw: moving from the bedside to the bench. Cells Tissues Organs (2008) 0.98
Targeting TGFβ signaling in subchondral bone and articular cartilage homeostasis. Trends Pharmacol Sci (2014) 0.96
The inhibitory effect of alendronate, a nitrogen-containing bisphosphonate on the PI3K-Akt-NFkappaB pathway in osteosarcoma cells. Br J Pharmacol (2005) 0.95
The resistance of cortical bone tissue to failure under cyclic loading is reduced with alendronate. Bone (2014) 0.94
A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. AIDS (2009) 0.94
Eel calcitonin (elcatonin) suppressed callus remodeling but did not interfere with fracture healing in the femoral fracture model of cynomolgus monkeys. J Bone Miner Metab (2009) 0.93
Bone metabolism and clinical study of 44 patients with bisphosphonate-related osteonecrosis of the jaws. Med Oral Patol Oral Cir Bucal (2012) 0.93
The effects of bisphosphonates on ectopic soft tissue mineralization caused by mutations in the ABCC6 gene. Cell Cycle (2015) 0.93
Involvement of interleukin-1 in the inflammatory actions of aminobisphosphonates in mice. Br J Pharmacol (2000) 0.93
Recovery of trabecular and cortical bone turnover after discontinuation of risedronate and alendronate therapy in ovariectomized rats. J Bone Miner Res (2008) 0.92
Treatment of immobilization-related hypercalcaemia with denosumab. Clin Kidney J (2012) 0.92
The combination therapy with alfacalcidol and risedronate improves the mechanical property in lumbar spine by affecting the material properties in an ovariectomized rat model of osteoporosis. BMC Musculoskelet Disord (2009) 0.91
Bisphosphonates in Breast Cancer Patients with Bone Metastases. Breast Care (Basel) (2010) 0.91
Alendronate enhances osteogenic differentiation of bone marrow stromal cells: a preliminary study. Clin Orthop Relat Res (2008) 0.91
Regulation of osteoclast polarization. Odontology (2007) 0.89
Bisphosphonate induced osteonecrosis of jaw in breast cancer patients: A systematic review. J Oral Maxillofac Pathol (2012) 0.89
A closer look at the immediate trabecula response to combined parathyroid hormone and alendronate treatment. Bone (2014) 0.87
Anatomic site variability in rat skeletal uptake and desorption of fluorescently labeled bisphosphonate. Oral Dis (2010) 0.87
Consequences of irradiation on bone and marrow phenotypes, and its relation to disruption of hematopoietic precursors. Bone (2014) 0.87
Assessment of corticosteroid-induced osteonecrosis in children undergoing chemotherapy for acute lymphoblastic leukemia: a report from the Japanese Childhood Cancer and Leukemia Study Group. J Pediatr Hematol Oncol (2014) 0.87
Bisphosphonates: effects on osteoblast. Eur J Clin Pharmacol (2012) 0.87
Once-yearly zoledronic acid in hip fracture prevention. Clin Interv Aging (2009) 0.86
Lack of correlation between duration of osteonecrosis of the jaw and sequestra tissue morphology: what it tells us about the condition and what it means for future studies. J Oral Maxillofac Surg (2010) 0.86
The effects of bisphosphonates on jaw bone remodeling, tissue properties, and extraction healing. Odontology (2011) 0.86
Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules. J Mater Sci Mater Med (2014) 0.85
Treatment of bisphosphonate-induced osteonecrosis of the jaws with Nd:YAG laser biostimulation. Lasers Med Sci (2011) 0.85
The effects of bone turnover rate on subchondral trabecular bone structure and cartilage damage in the osteoarthritis rat model. Rheumatol Int (2009) 0.85
Pathogenesis of aortic stenosis: not just a matter of wear and tear. Am J Cardiovasc Dis (2011) 0.85
Osteonecrosis of jaws related to intravenous bisphosphonates: the experience of a Jordanian teaching hospital. Ann R Coll Surg Engl (2010) 0.84
The effects of zoledronic acid in the bone and vasculature support of hematopoietic stem cell niches. J Cell Biochem (2013) 0.84
Bone densitometry in pediatric patients treated with pamidronate. Pediatr Radiol (2005) 0.83
New methodology for evaluating osteoclastic activity induced by orthodontic load. J Appl Oral Sci (2015) 0.83
Severe resistant hypocalcemia in multiple myeloma after zoledronic acid administration: a case report. J Med Case Rep (2014) 0.83
Prevalence, pathophysiology, screening and management of osteoporosis in gastric cancer patients. J Gastric Cancer (2011) 0.82
Bisphosphonate-related osteonecrosis of the jaw: a review of the literature. Int J Dent (2014) 0.82
Amorphous calcium phosphate-mediated binding of matrix metalloproteinase-9 to fibrin is inhibited by pyrophosphate and bisphosphonate. Inflammation (1999) 0.82
Identification of secondary targets of N-containing bisphosphonates in mammalian cells via parallel competition analysis of the barcoded yeast deletion collection. Genome Biol (2009) 0.81
Bisphosphonate associated osteonecrosis of the jaw: an update on pathophysiology, risk factors, and treatment. Int J Dent (2014) 0.81
Alendronate blocks metalloproteinase secretion and bone collagen I release by PC-3 ML cells in SCID mice. Clin Exp Metastasis (1998) 0.81
A systematic review of microsurgical reconstruction of the jaws using vascularized fibula flap technique in patients with bisphosphonate-related osteonecrosis. J Appl Oral Sci (2011) 0.81
American Society of Biomechanics Journal of Biomechanics Award 2013: cortical bone tissue mechanical quality and biological mechanisms possibly underlying atypical fractures. J Biomech (2015) 0.80
Fragility fractures of the pelvis. Curr Rev Musculoskelet Med (2012) 0.80
Osteonecrosis of the jaws and bisphosphonate treatment in cancer patients. Wien Klin Wochenschr (2006) 0.80
Inhibition of inflammatory actions of aminobisphosphonates by dichloromethylene bisphosphonate, a non-aminobisphosphonate. Br J Pharmacol (1999) 0.80
Efficacy of low doses of pamidronate in osteopenic patients administered in the early post-renal transplant. Osteoporos Int (2010) 0.80
Are bisphosphonates effective in the treatment of osteoarthritis pain? A meta-analysis and systematic review. PLoS One (2013) 0.80
Bisphosphonates in bone cement inhibit PMMA particle induced bone resorption. Ann Rheum Dis (1998) 0.79
Pathologic fractures in bisphosphonate-related osteonecrosis of the jaw-review of the literature and review of our own cases. Craniomaxillofac Trauma Reconstr (2013) 0.79
Adjuvant pamidronate therapy prevents the development of bone metastases in breast cancer patients with four or more positive nodes. Oncol Lett (2010) 0.79
Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis (1998) 0.79
Phosphate: an old bone molecule but new cardiovascular risk factor. Br J Clin Pharmacol (2014) 0.79
Advanced glycation end products play adverse proinflammatory activities in osteoporosis. Mediators Inflamm (2014) 0.79
Efficacy of intravenous alendronate for the treatment of glucocorticoid-induced osteoporosis in children with autoimmune diseases. Clin Rheumatol (2008) 0.79
The effects of zoledronate on the survival and function of human osteoblast-like cells. BMC Musculoskelet Disord (2015) 0.78
Osteoblastic protein tyrosine phosphatases inhibition and connexin 43 phosphorylation by alendronate. Exp Cell Res (2014) 0.78
The Effect of Teriparatide on Fracture Healing of Osteoporotic Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int (2016) 0.78
Comparative effects of antiresorptive agents on bone mineral density and bone turnover in postmenopausal women. Clin Interv Aging (2006) 0.78
Bisphosphonates in the adjuvant treatment of cancer: experimental evidence and first clinical results. International Bone and Cancer Study Group (IBCG). Br J Cancer (2000) 0.78
Effects of clodronate and alendronate on osteoclast and osteoblast co-cultures on silk-hydroxyapatite films. Acta Biomater (2013) 0.78
Bisphosphonate-related osteonecrosis of the jaws (Bronj). Med Oral Patol Oral Cir Bucal (2013) 0.78
The Local Effect of Alendronate with Intra-alveolar Collagen Sponges on Post Extraction Alveolar ridge Resorption: A Clinical Trial. J Maxillofac Oral Surg (2014) 0.77
Enhanced affinity bifunctional bisphosphonates for targeted delivery of therapeutic agents to bone. Bioconjug Chem (2011) 0.77
The protective effects of incadronate on inflammation and joint destruction in established rat adjuvant arthritis. Rheumatol Int (2005) 0.77
Isoprenoid biosynthesis in Plasmodium falciparum. Eukaryot Cell (2014) 0.77
Effects of dried plum supplementation on bone metabolism in adult C57BL/6 male mice. Calcif Tissue Int (2013) 0.77
Alendronate-Eluting Biphasic Calcium Phosphate (BCP) Scaffolds Stimulate Osteogenic Differentiation. Biomed Res Int (2015) 0.77
Dual Effects of Bisphosphonates on Ectopic Skin and Vascular Soft Tissue Mineralization versus Bone Microarchitecture in a Mouse Model of Generalized Arterial Calcification of Infancy. J Invest Dermatol (2016) 0.76
Inositol hexakisphosphate inhibits osteoclastogenesis on RAW 264.7 cells and human primary osteoclasts. PLoS One (2012) 0.76
Effects of the bisphosphonate risedronate on osteopenia in OASIS-deficient mice. J Bone Miner Metab (2009) 0.76
Does estrogen play a role in response to adjuvant bone-targeted therapies? J Bone Oncol (2013) 0.76
The effect of sequential therapy for postmenopausal women with osteoporosis: A PRISMA-compliant meta-analysis of randomized controlled trials. Medicine (Baltimore) (2016) 0.75
Aromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivo. Oncotarget (2017) 0.75
Hypercalcemia of Malignancy. J Adv Pract Oncol (2015) 0.75
Systemic and local zoledronic acid treatment with hydroxyapatite bone graft: A histological and histomorphometric experimental study. Exp Ther Med (2016) 0.75
Bone marker response in chronic diffuse sclerosing osteomyelitis treated with intravenous ibandronate. Ann Rheum Dis (2006) 0.75
Zoledronic acid in metastatic osteosarcoma: encouraging progression free survival in four consecutive patients. Clin Sarcoma Res (2016) 0.75
A comparative study of zoledronic acid and once weekly Alendronate in the management of acute Charcot arthropathy of foot in patients with diabetes mellitus. Indian J Endocrinol Metab (2013) 0.75
Are macrophages in tumors good targets for novel therapeutic approaches? Mol Cells (2014) 0.75
Effect of low-level laser therapy on bisphosphonate-treated osteoblasts. Maxillofac Plast Reconstr Surg (2016) 0.75
Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med (1995) 10.99
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med (1990) 4.10
Requirement of pp60c-src expression for osteoclasts to form ruffled borders and resorb bone in mice. J Clin Invest (1992) 3.40
Bisphosphonates promote apoptosis in murine osteoclasts in vitro and in vivo. J Bone Miner Res (1995) 3.23
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy. Am J Med (1993) 3.23
The when and how of Src regulation. Cell (1993) 3.07
Bisphosphonate action. Alendronate localization in rat bone and effects on osteoclast ultrastructure. J Clin Invest (1991) 2.63
Diphosphonates inhibit hydroxyapatite dissolution in vitro and bone resorption in tissue culture and in vivo. Science (1969) 2.30
Two modes of action of bisphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner (1986) 2.23
Diphosphonates inhibit formation of calcium phosphate crystals in vitro and pathological calcification in vivo. Science (1969) 2.20
Effect of ethane-1-hydroxy-1,1-diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of rats. Calcif Tissue Res (1973) 1.85
The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J Clin Invest (1993) 1.84
Inhibition of osteoclast-like cell formation by bisphosphonates in long-term cultures of human bone marrow. J Clin Invest (1989) 1.79
The binding of pyrophosphate and two diphosphonates by hydroxyapatite crystals. Calcif Tissue Res (1973) 1.77
Bisphosphonates act on rat bone resorption through the mediation of osteoblasts. J Clin Invest (1993) 1.58
A new model for the regulation of bone resorption, with particular reference to the effects of bisphosphonates. J Bone Miner Res (1996) 1.40
Effects of bisphosphonates on isolated rat osteoclasts as examined by reflected light microscopy. J Bone Miner Res (1990) 1.35
Effect of bisphosphonates on proliferation and viability of mouse bone marrow-derived macrophages. J Bone Miner Res (1987) 1.35
Structure-activity relationships of various bisphosphonates. Calcif Tissue Int (1983) 1.31
The acute-phase response after bisphosphonate administration. Calcif Tissue Int (1987) 1.29
The effects of risedronate on canine cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling site. J Bone Miner Res (1995) 1.29
The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci (1972) 1.26
The effects of diphosphonates on the growth and glycolysis of connective-tissue cells in culture. Biochem J (1978) 1.26
Changes in bone histomorphometry after long-term treatment with intermittent, cyclic etidronate for postmenopausal osteoporosis. J Bone Miner Res (1993) 1.24
Bisphosphonates induce osteoblasts to secrete an inhibitor of osteoclast-mediated resorption. Endocrinology (1996) 1.24
Studies on x ray absorption and diffraction of bone tissue. Acta Anat (Basel) (1952) 1.20
Protein-tyrosine phosphatase activity regulates osteoclast formation and function: inhibition by alendronate. Proc Natl Acad Sci U S A (1996) 1.14
Bisphosphonates act on osteoblastic cells and inhibit osteoclast formation in mouse marrow cultures. Bone (1996) 1.07
Influence of a diphosphonate on the cellular aspect of young bone tissue. Calcif Tissue Int (1980) 1.06
Continuous therapy with pamidronate, a potent bisphosphonate, in postmenopausal osteoporosis. J Clin Endocrinol Metab (1994) 1.03
Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethylaminohydroxypropylidene bisphosphonate. J Bone Miner Res (1995) 1.00
Clinical effects of bisphosphonates in involutional osteoporosis. J Bone Miner Res (1993) 0.98
Effects of one-year cyclical treatment with clodronate on postmenopausal bone loss. Bone (1993) 0.97
The subcellular distribution of [14C]dichloromethylenebisphosphonate and [14C]1-hydroxyethylidene-1,1-bisphosphonate in cultured calvaria cells. Calcif Tissue Int (1984) 0.95
Alendronate distributed on bone surfaces inhibits osteoclastic bone resorption in vitro and in experimental hypercalcemia models. Bone (1995) 0.94
Lipophilic 1,1-bisphosphonates are potent squalene synthase inhibitors and orally active cholesterol lowering agents in vivo. J Biol Chem (1993) 0.93
Renal secretion of diphosphonates in rats. Kidney Int (1975) 0.91
The effect of several diphosphonates on acid phosphohydrolases and other lysosomal enzymes. Biochim Biophys Acta (1976) 0.87
Inhibitory effects of bisphosphonates on growth of amoebae of the cellular slime mold Dictyostelium discoideum. J Bone Miner Res (1994) 0.87
Importance of the paracellular pathway for the transport of a new bisphosphonate using the human CACO-2 monolayers model. Biochem Pharmacol (1993) 0.86
Retention of etidronate in human, dog, and rat. J Bone Miner Res (1992) 0.85
Acid extrusion is induced by osteoclast attachment to bone. Inhibition by alendronate and calcitonin. J Clin Invest (1995) 0.84
Human protein tyrosine phosphatase-sigma: alternative splicing and inhibition by bisphosphonates. J Bone Miner Res (1996) 0.83
Effects of two novel bisphosphonates on bone cells in vitro. Bone Miner (1994) 0.83
The influence of 1-hydroxyethane-1,1-diphosphonate and dichloromethanediphosphonate on lysine hydroxylation and cross-link formation in rat bone, cartilage and skin collagen. Biochem J (1981) 0.80
c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling. Science (1994) 5.97
Mechanisms of action of bisphosphonates. Annu Rev Pharmacol Toxicol (1998) 1.39
The pharmacology of bisphosphonates and new insights into their mechanisms of action. J Bone Miner Res (1999) 1.30
The influence of two diphosphonates on calcium metabolism in the rat. Clin Sci (1972) 1.26
The inhibitory effect of phosphonates on the formation of calcium phosphate crystals in vitro and on aortic and kidney calcification in vivo. Eur J Clin Invest (1970) 1.18
Inhibition of vitamin D metabolism by ethane-1-hydroxyl-1, 1-diphosphonate. Arch Biochem Biophys (1974) 0.90
The influence of a diphosphonate on the intestinal absorption of calcium. Isr J Med Sci (1971) 0.88
Rapid intracellular degradation of newly synthesized collagen by bone cells. Effect of dichloromethylenebisphosphonate. Biochim Biophys Acta (1982) 0.75
Diphosphonates and vitamin-D metabolism in Paget's disease. Lancet (1973) 0.75